Silo Wellness Announces LOI to Acquire NUGL/Kaya in a Transaction Valued at CAD $43,289,624.60; CSE to Halt Trading Until Shareholder Approval | Psychedelic Invest

Silo Pharma, Inc. (Nasdaq: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, announced today that it has retained the services of Clarivate™, a leading global provider of information services including IP lifecycle management solutions. Under terms of the agreement, Clarivate will manage, maintain, and track the Company’s intellectual property assets and…

Frazier Healthcare Acquires RevSpring to Bolster Payment Solutions in Healthcare

What You Should Know: – Frazier Healthcare Partners, a leading healthcare investment firm, announced today the successful acquisition of RevSpring. – RevSpring, a provider of

March 12, 2024

Opinion | Dark Humor Allows Us to See the ‘Light’ in Medicine

Lazarus is an adjunct professor of psychiatry. During a visit to our daughter and her family in Columbus, Ohio, my wife and I went grocery

November 4, 2024

Elahere secures full approval from FDA for types of ovarian cancer – Pharmaceutical Technology

Share this article The FDA has granted full approval to Elahere after it granted priority review in December 2023. Credit: Maxx-Studio via Shutterstock. AbbVie’s monoclonal

March 25, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.